Tifenn Wauquier

Tifenn Wauquier

Auto-generated profile, based on publicly available information

Tifenn Wauquier

Université Paris Cité, Institut Imagine, Laboratory of Neurogenetics and Neuroinflammation, INSERM UMR 1163, 1 Paris

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2026 in Journal of Experimental Medicine
Verified
Journal Article
Open access
CDClémence David
Clémence David
TWTifenn Wauquier
Tifenn Wauquier
ABAlix de Becdelièvre
Alix de Becdelièvre
CLCamille Louvrier
Camille Louvrier
MTMaud Tusseau
Maud Tusseau
MFMarie-Louise Frémond
Marie-Louise Frémond
COPA syndrome is a rare monogenic autoinflammatory disease due to heterozygous mutations in COPA, encoding the coatomer subunit α. COPA syndrome demonstrates phenotypic overlap with STING-associated vasculopathy with onset in infancy (SAVI), the latter due to gain-of-function mutations in STING1. Indeed, STING activation is a key driver of the pathogenesis of COPA syndrome, and a recent report suggested that the presence of the common HAQ STING allele confers complete protection against the development of clinical disease in the context of pathogenic heterozygous mutations in COPA. Given the potential significance of this result for patient management, we investigated the STING HAQ haplotype status of a separate cohort of individuals segregating pathogenic mutations in COPA. In doing so, we ascertained five HAQ-negative, clinically asymptomatic individuals aged 30, 39, 39, 42, and 43 years at last evaluation, and an HAQ-positive male with kidney disease that we consider most likely attributable to the recurrent R233H mutation in COPA. Our findings challenge the suggestion that STING haplotype status is the sole determinant of clinical penetrance in COPA syndrome.

4 June 2025 in Journal of Human Immunity
Verified
Journal Article
Open access
CWCallie C.Y. Wong
Callie C.Y. Wong
TWTifenn Wauquier
Tifenn Wauquier
CUCarolina Uggenti
Carolina Uggenti
CSColin Stok
Colin Stok
ALAlice Lepelley
Alice Lepelley
YCYanick J. Crow
Yanick J. Crow
Spondyloenchondrodysplasia (SPENCD) is a rare immuno-osseus disease due to biallelic mutations in ACP5, resulting in a loss of tartrate-resistant acid phosphatase (TRAP) activity and enhanced type I interferon signalling. While TRAP was identified in the 1950s, ACP5 was cloned in the 1990s, an Acp5 knockout mouse was reported in 1996, and >3,000 articles are retrievable on PubMed using the terms “tartrate-resistant acid phosphatase” + “TRAP”, the immunopathology of SPENCD remains unclear. Here we describe the clinical phenotype and molecular architecture of SPENCD, review the biology of TRAP, and consider how TRAP deficiency leads to disturbed innate immunity.